|
A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC). |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Merck; Pfizer |
Consulting or Advisory Role - Amphista Therapeutics; Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Janssen; Merck; Novartis; Pfizer; Roche |
Research Funding - Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Roche |
Expert Testimony - Merck/Pfizer; MSD |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Janssen; Merck; Merck |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Elsevier (Inst); Roche/Genentech (Inst) |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Guardant Health (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Orion; Oxcia |
Research Funding - Amgen; AstraZeneca; MSD; Roche; Scancell Ltd.; Sun Pharma |
|
|
Consulting or Advisory Role - AstraZeneca |
Speakers' Bureau - GlaxoSmithKline; MSD; Pfizer; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - Named on patent held by the Institute of Cancer Research (ICR) together with Cancer Research UK identifying JMJD6 as a therapeutic target in advanced prostate cancer. (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Faron Pharmaceuticals |
Travel, Accommodations, Expenses - Faron Pharmaceuticals |
|
|
Stock and Other Ownership Interests - Bottega Organica; Oncosense |
Research Funding - Dompé Farmaceutici (Inst); IBSA (Inst) |
Patents, Royalties, Other Intellectual Property - Fondazione Per L'istituto Oncologico Di Ricerca, Altergon, Arbormentis; Fondazione Per L'istituto Oncologico Di Ricerca, Altergon, Arbormentis (Inst) |
(OPTIONAL) Uncompensated Relationships - Astellas Pharma; AstraZeneca; Global FZE; Sun Pharma |
|
|
Honoraria - Astex Pharmaceuticals; MSD |
Consulting or Advisory Role - Charm Therapeutics; D. E. Shaw Research |
Travel, Accommodations, Expenses - Nurix; Roche/Genentech; Sanofi |
|
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi Aventis GmbH |
Speakers' Bureau - AstraZeneca |
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Harpoon (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst) |
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi |